Assessment of the Effectiveness of Chlortalidone in Patients with Arterial Hypertension in Real Clinical Practice
The aim of the study was to investigate the possibility of increasing the hypotensive effect in patients who did not reach the target blood pressure level in routine outpatient practice by replacing indapamide or hydrochlorothiazide with chlorthalidone in the complex pharmacotherapy regimen, as well as to evaluate the effect of treatment modification on vascular wall stiffness and volemic status of the examined patients. The pilot study included 35 patients with stage I–III hypertension, who received antihypertensive therapy and had not achieved the target blood pressure level at the time of screening. The study design involved replacing hydrochlorothiazide or indapamide with chlorthalidone (Dikardplus) at an initial dose of 12.5 mg/day. During therapy, the dynamics of blood pressure, heart rate, arterial stiffness indices, and volemic status were assessed. Conclusion. The use of chlortalidone in patients with arterial hypertension led to a significant decrease in systolic and diastolic blood pressure (p = 0.000007 and p = 0.015, respectively), achieving the target blood pressure level in the vast majority (n = 27) of patients. There was a tendency to decrease vascular stiffness in patients with arterial hypertension while taking chlortalidone, while no significant changes in volemic status were observed (p > 0.05).
Luneva Yu.V., Povetkin S.V., Klyueva E.G., Bredikhina P.V. 2025. Assessment of the Effectiveness of Chlortalidone in Patients with Arterial Hypertension in Real Clinical Practice. Challenges in Modern Medicine, 48(2): 183–193 (in Russian). DOI: 10.52575/2687-0940-2025-48-2-183-193. EDN: FZSEHL
While nobody left any comments to this publication.
You can be first.
Aviva Petri, Caroline Sabin. 2021. Visual Medical Statistics 4th Edition, Revised and Supplemented. Translation from English Edited by V.P. Leonov. Moscow, Geotar Media Publishing Group. 40 (in Russian).
Kobalava Zh.D., Konradi A.O., Nedogoda S.V., Shlyakhto E.V., Arutyunov G.P., Baranova E.I., Barbarash O.L., Bobkova N.V., Boytsov S.A., Bubnova M.G., Vavilova T.V., Villevalde S.V., Galyavich A.S., Glezer M.G., Grineva E.N., Grinstein Yu.I., Drapkina O. M., O.M., Zhernakova Yu.V., Zvartau N.E., Irtyuga O.B., Kislyak O.A., Koziolova N.A., Kosmacheva E.D., Kotovskaya Yu.V., Yu.V., Libis R.A., Lopatin Yu.M., Nebiridze D.V., Nedoshivin A.O., Nikulina S.Yu., Ostroumova O.D., Oschepkova E.V., Ratova L.G., Salasiuk A.S., Skibitsky V.V., Tkacheva O.N., Troitskaya E.A., Chazova I.E., Chesnikova A.I., Chumakova G.A., Shalnova S.A., Shestakova M.V., Yakushin S.S., Yanishevsky S.N. 2024 Clinical Practice Guidelines for Hypertension in Adults. Russian Journal of Cardiology. 2024; 29(9): 6117 (in Russian). doi: 10.15829/1560-4071-2024-6117. EDN: GUEWLU.
Kobalava Zh.D., Konradi A.O., Nedogoda S.V., Shlyakhto E.V., Arutyunov G.P., Baranova E.I., Barbarash O.L., Boitsov S.A., Vavilova T.V., Villevalde S.V., Galyavich A.S., Glezer M.G., Grineva E.N., Grinstein Yu.I., Drapkina O.M., Zhernakova Yu.V., Zvartau N.E., Kislyak O.A., Koziolova N.A., Kosmacheva E.D., Kotovskaya Yu.V., Libis R.A., Lopatin Yu.M., Nebiridze D.V., Nedoshivin A.O., Ostroumova O.D., Oschepkova E.V., Ratova L.G., Skibitsky V.V., Tkacheva O.N., Chazova I.E., Chesnikova A.I., Chumakova G.A., Shalnova S.A., Shestakova M.V., Yakushin S.S., Yanishevsky S.N. 2020. Arterial Hypertension in Adults. Clinical Guidelines 2020. Russian Journal of Cardiology. 2020; 25(3): 3786 (in Russian). doi:10.15829/1560-4071-2020-3-3786
Netchessova T. 2021. Chlortalidone in Modern Recommendations for Treatment of Arterial Hypertension. Cardiology in Belarus; 13 (3): 486–492 (in Russian) doi:10.34883/PI.2021.13.3.013
Ozerova M.S., Nikulina L.D. 2008. Analysis of Changes in the Balance of Water Sectors of the Using the Bioimpedansometry Method in Patients with Hypertension. Materials of the 10th Scientific and Practical Conference “Diagnostics and Treatment of Disorders of Regulation of the Cardiovascular System” Moscow, Main Clinical Hospital of the Ministry of Internal Affairs of Russia. M. P. 456–463. (in Russian).
Pavlova Z.Sh., Pyanykh O.P., Golodnikov I.I. 2020. Bioimpedance Analysis: Clinical Examples and Interpretation of Changes in Human Body Composition under the Influence of Various Factors. Endocrinology: News, Opinions, Training. 9(4): 74–81 (in Russian). doi: 10.33029/2304-9529-2020-9-4-74-81
Tsygankova D.P., Fedorova N.V. 2020. Selected Socio-Economic Aspects of the Risk of Hypertension. "Arterial’naya Gipertenziya". 26(2): 155–162 (in Russian). doi: 10.18705/1607-419X-2020-26-2-155-162
Shishko V.I., Karpovich O.A., Kornelyuk D.G., Shulga E.V., Larionova I.N., Zhmakina E.N. 2022. Comparative Efficacy of Chlorthalidone and Hydrochlorothiazide in Combination Treatment of Patients with Stage I–II Arterial Hypertension with Abdominal Obesity. Cardiology in Belarus. 14(1): 116–124 (in Russian). doi: 10.34883/PI.2022.14.1.011
Agarwal R., Sinha A.D., Cramer A.E., Balmes-Fenwick M., Dickinson J.H., Ouyang F., Tu W. 2021. Chlorthalidone for Hypertension in Advanced Chronic Kidney Disease. N. Engl. J. Med.; 385(27): 2507–2519. doi: 10.1056/NEJMoa2110730. Epub 2021 Nov 5. PMID: 34739197; PMCID: PMC9119310.
Anil Pareek, Franz H. Messerli, Gustavo Saravia, Ravi Tejraj. 2020. MehtaInteramerican Society of Cardiology (IASC) Position Statement: Chlorthalidone vs. Thiazide-Type Diuretics. International Journal of Cardiology Hypertension. 7. 100054. doi: 10.1016/j.ijchy.2020.100054
Dineva S., Uzunova K., Pavlova V., Filipova E., Kalinov K., Vekov T. 2021. Network Meta-Analysis of Efficacy and Safety of Chlorthalidone and Hydrochlorothiazide in Hypertensive Patients. Blood Press Monit. 26(2): 160–168. doi: 10.1097/MBP.0000000000000486. PMID: 32909966; PMCID: PMC7932752]
Dorsch M.P., Gillespie B.W., Erickson S.R., Bleske B.E., Weder A.B. 2011. Chlorthalidone Reduces Cardiovascular Events Compared with Hydrochlorothiazide: A Retrospective Cohort Analysis. Hypertension. 57(4): 689–94. doi: 10.1161/HYPERTENSIONAHA.110.161505
Hripcsak G., Suchard M.A., Shea S. 2020. Comparison of Cardiovascular and Safety Outcomes of Chlorthalidone vs Hydrochlorothiazide to Treat Hypertension. JAMA Intern Med.; 80(4): 542–551. doi:10.1001/jamainternmed.2019.7454
Kim H.L., Lim W.H., Seo J.B., et al. 2021. Prognostic Value of Arterial Stiffness According to the Cardiovascular Risk Profiles. Journal of Human Hypertension; 35(11): 978–984. doi: 10.1038/s41371-020-00441-z
Matthews K.A., Brenner M.J., Brenner A.C. 2013. Evaluation of the Efficacy and Safety of a Hydrochlorothiazide to Chlorthalidone Medication Change in Veterans with Hypertension. Clin. Ther; 35(9): 1423–30. doi: 10.1016/j.clinthera.2013.07.430
Miyoshi T., Ito H. 2021. Arterial Stiffness in Health and Disease: The Role of Cardio-Ankle Vascular Index // Journal of Cardiology. 78(6). 493–501. doi: 10.1016/j.jjcc.2021.07.011
Morioka T., Mori K., Emoto M. 2021. Is Stiffness Parameter β Useful for the Evaluation of Atherosclerosis? Its Clinical Implications, Limitations, and Future Perspectives. J. Atheroscler. Thromb. 28(5): 435–453. doi: 10.5551/jat.RV17047
Nigel S. Beckett, Ruth Peters, Astrid E Fletcher, Jan A Staessen, Lisheng Liu, Dan Dumitrascu, Vassil Stoyanovsky, Riitta L. Antikainen, Yuri Nikitin, Craig Anderson, Alli Belhani, Francoise Forette, Chakravarthi Rajkumar, Lutgarde Thijs, Winston Banya, Christopher J. Bulpitt, T. McCormack, John Potter, B. G. Extremera, Peter Sever, HYVET Study Group. 2008. Treatment of Hypertension in Patients 80 Years of Age or Older. N. Engl. J. Med. 358: 1887–98. doi: 10.1056/NEJMoa0801369
Roush G.C., Messerli F.H. 2021. Chlorthalidone Versus Hydrochlorothiazide: Major Cardiovascular Events, Blood Pressure, Left Ventricular Mass, and Adverse Effects. J Hypertens. 39(6): 1254–1260. doi: 10.1097/HJH.0000000000002771
Sue Hughes. 2022. Diuretic Agents Equal to Prevent CV Events in Hypertension: DCP - Medscape - Nov 05, 2022.
The ALLHAT Collaborative Research Group. 2002. Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 288: 2981–97. doi: 10.1001/jama.288.23.2981